Evidence map›Paper›PMID 36413215›Full record

ArticleArthritis & rheumatology (Hoboken, N.J.)2023

Cell-Mediated Cytotoxicity in Lyme Arthritis.

David Ordóñez, Robert B Lochhead, Klemen Strle, Annalisa Pianta, Sheila Arvikar, Ildiko Van Rhijn, Anat Stemmer-Rachamimov, Allen C Steere

Open access · greenAbstract read
In one paragraph

Article in Arthritis & rheumatology (Hoboken, N.J.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Lyme Arthritis: A 50-Year Journey.The Journal of infectious diseases · 2024
    Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

David OrdóñezMassachusetts General Hospital and Harvard Medical School, Boston.ORCID 0000-0003-0738-8653
Robert B LochheadMassachusetts General Hospital and Harvard Medical School, Boston.
Klemen StrleMassachusetts General Hospital and Harvard Medical School, Boston.
Annalisa PiantaMassachusetts General Hospital and Harvard Medical School, Boston.
Sheila ArvikarMassachusetts General Hospital and Harvard Medical School, Boston.
Ildiko Van RhijnBrigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Anat Stemmer-RachamimovMassachusetts General Hospital and Harvard Medical School, Boston.
Allen C SteereMassachusetts General Hospital and Harvard Medical School, Boston.ORCID 0000-0002-5268-9853
Harvard University · USBrigham and Women's Hospital · US

Funding

Research Training in Rheumatology at Massachusetts General HospitalT32AR007258 · NIAMS · MASSACHUSETTS GENERAL HOSPITAL · PI ANDREW D LUSTER · 1986 to 2026
$6.9M
Borrelia burgdorferi-Induced Autoimmunity in Lyme DiseaseR01AI101175 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI STEERE, ALLEN C · 2013 to 2021
$3.6M
Cellular and humoral immunity in Lyme arthritisR01AI144365 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI STEERE, ALLEN C · 2019 to 2023
$2.9M
Extracellular vesicles, small RNAs, and intercellular communication in Entamoeba histolyticaR21AI125764 · NIAID · STANFORD UNIVERSITY · PI SINGH, UPINDER · 2016 to 2017
$435k
MHC class II presentation of Borrelia burgdorferi and synovial tissue antigens in murine Lyme arthritisR21AI148982 · NIAID · MEDICAL COLLEGE OF WISCONSIN · PI LOCHHEAD, ROBERT · 2020 to 2021
$424k
Defining Microbial and Host Factors in Innate Immune Responses in Lyme ArthritisK01AR062098 · NIAMS · MASSACHUSETTS GENERAL HOSPITAL · PI STRLE, KLEMEN · 2012 to 2014
$398k
Pathogenic and Diagnostic Implications of MicroRNAs in Lyme Disease.F32AI126764 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI LOCHHEAD, ROBERT · 2016 to 2017
$59k
NIAID NIH HHS F32 AI126764NIAID NIH HHS R01 AI101175NIAID NIH HHS R01 AI144365NIAID NIH HHS R21 AI125764NIAID NIH HHS R21 AI148982NIAMS NIH HHS K01 AR062098NIAMS NIH HHS T32 AR007258
6 · The paper itself

Abstract

objectiveObliterative microvascular lesions are found in the synovial tissue of ~50% of patients with post-antibiotic Lyme arthritis (LA) and correlate with autoantibodies to certain vascular antigens. In this study, we identified lymphocytes with cytotoxic potential that may also mediate this feature of synovial pathology.

methodsThe cytotoxic potential of lymphocytes and their T cell receptor (TCR) V

resultsIn SFMC and PBMC samples, the percentages of CD8+ T cells and double-negative T cells (primarily γδ T cells) were greater among 22 patients with post-antibiotic LA than in 14 patients with antibiotic-responsive LA. Moreover, CD8+ T cells and γδ T cells often expressed cytotoxic mediators, granzyme A/granzyme B, and perforin. The same 3 TCR V

conclusionWe propose that CD8+ T cell-mediated cytotoxicity, CD4+ T cell help, autoantibodies to vascular antigens, and complement deposition may each have a role in microvasculature damage in post-antibiotic LA.

Indexed as

Leukocytes, MononuclearLyme DiseaseAnti-Bacterial AgentsAutoantibodiesCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesHumansReceptors, Antigen, T-Cell, alpha-betaSynovial FluidAnti-Bacterial AgentsAutoantibodiesReceptors, Antigen, T-Cell, alpha-beta

Identifiers

PMID36413215
PMCPMC10191881
OpenAlexW4309664060

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.